Oxandrolone is a synthetic anabolic–androgenic steroid derived from dihydrotestosterone (DHT), first synthesised in 1962 and distinguished by an oxygen atom replacing the carbon-2 position in its A-ring — a structural modification that substantially increases anabolic potency whilst markedly reducing androgenic activity relative to testosterone.
Mechanism & Pharmacology
Oxandrolone binds the androgen receptor (AR) with a binding affinity approximately 0.6 times that of testosterone but produces a disproportionately strong anabolic signal due to its resistance to aromatase-mediated conversion to oestrogen. Because oxandrolone is a DHT derivative, aromatase — the CYP19A1 enzyme responsible for converting androgens into oestrogens — does not act upon its A-ring, making oestrogenic side effects (water retention, gynaecomastia) essentially absent at typical dosages.
The compound exhibits an oral bioavailability of approximately 97%, an exceptionally high figure for any 17α-alkylated oral steroid. This alkylation at the 17-alpha position allows oxandrolone to survive first-pass hepatic metabolism, though it does impose a degree of hepatotoxicity that is considered modest in comparison to compounds such as oxymetholone or stanozolol. The plasma half-life sits at roughly 9–10 hours, necessitating a twice-daily dosing schedule to maintain stable serum concentrations throughout the day.
At the cellular level, oxandrolone increases nitrogen retention within skeletal muscle, upregulates IGF-1 expression in muscle tissue, and suppresses glucocorticoid receptor activity — meaning it partially antagonises the catabolic signalling of cortisol. This combination of anabolic promotion and anti-catabolic action is central to its reputation for lean, dry mass preservation. Oxandrolone does not convert to DHT via 5α-reductase in peripheral tissues (it is already a DHT derivative), which substantially limits scalp, skin, and prostate-related androgenic effects. Endogenous testosterone suppression occurs but tends to be less pronounced than with more androgenic compounds, though it remains meaningful and post-cycle recovery protocols are standard practice.
Application Context & User Groups
Oxandrolone occupies a well-defined position in performance sport: it is the prototypical "cutting" or "strength" oral compound, favoured in contexts where the goal is quality muscular retention during caloric restriction rather than rapid mass accumulation. Because it does not cause significant water retention, gains made on oxandrolone tend to appear lean and defined — a characteristic that has made it a staple in physique preparation phases.
In clinical medicine, oxandrolone has an established therapeutic track record. It is FDA-approved for the treatment of involuntary weight loss associated with severe burns, HIV/AIDS wasting syndrome, and certain muscular dystrophies. Research published in peer-reviewed journals has demonstrated its efficacy in preserving lean body mass during catabolic illness at doses of 5–20mg per day. This medical background gives the compound a comparatively well-characterised safety and pharmacokinetic profile compared to many non-approved anabolic agents.
Among physique athletes, oxandrolone is frequently incorporated into stacks rather than used as a standalone compound. Competitive bodybuilders in the final 8–12 weeks of contest preparation commonly combine it with non-aromatising agents such as testosterone propionate, trenbolone acetate, or masteron. The lack of oestrogenic activity makes management of oestrogen levels during a cycle simpler, which is particularly valued by those sensitive to water retention or who compete in divisions rewarding extreme muscularity and conditioning.
Powerlifters and strength athletes represent another core user group. Controlled studies in elderly populations have documented strength improvements from oxandrolone supplementation without corresponding increases in bodyweight, a finding consistent with anecdotal reports from strength sports competitors who use it for strength-to-weight ratio enhancement. Female athletes historically tolerate oxandrolone better than most other anabolic steroids owing to its low androgenic index; virilisation risk exists but is substantially lower than with compounds like stanozolol or testosterone, and doses in the 5–10mg range are most commonly referenced in this context.
Beginners considering their first oral anabolic cycle often encounter oxandrolone as a recommended entry point. The reduced androgenic burden, absence of oestrogen conversion, and well-documented pharmacology make it a more manageable compound than alternatives such as dianabol or anadrol, though newcomers should understand that "mild" is relative and all anabolic steroids carry meaningful health implications.
Range & Selection by Concentration and Pack Size
The oxandrolone category in this store spans 27 products from 24 manufacturers, offered across two distinct concentration tiers — 10mg per tablet and 50mg per tablet — with pack sizes of 50, 100, and 105 tablets.
10mg Tablets — Precision and Flexibility
The 10mg tier is the most widely stocked concentration and suits users who require granular dose control. This tier accommodates lower therapeutic-range dosing (20–40mg daily, achieved with 2–4 tablets), mid-range performance doses (40–60mg), and is particularly appropriate for female athletes working within the 5–10mg bracket where a single tablet can be halved if needed. Representative options include Oxandrolon 10mg by Balkan Pharmaceuticals, a product from one of Eastern Europe's most established licensed manufacturers, available in 100-tablet packs; Anavar-Lite 10mg by Beligas Pharmaceuticals in a convenient 50-tablet pack for those seeking a shorter initial trial; OxaTrex 10mg by Concentrex Labs in 100-tablet format; and Anavar 10 by Dragon-Pharma, also in 100-tablet packs, from a manufacturer with broad international recognition. The 105-tablet pack size found among certain 10mg offerings provides a minor cost-efficiency advantage for users running standard 8-week cycles.
50mg Tablets — Economy for Experienced Users
The 50mg tier is designed for experienced users running higher daily doses in the 50–100mg range who prefer fewer tablets per day. Splitting a single 50mg tablet allows a straightforward 25mg-per-dose twice-daily protocol. Pro-Anavar 50mg by Beligas Pharmaceuticals and Anavar 50 by Dragon-Pharma, both in 100-tablet packs, represent the primary options at this concentration level. At 100 tablets of 50mg, a single pack delivers 5,000mg of active compound — sufficient for approximately 10 weeks at 50mg per day or 5 weeks at 100mg per day, making these packs the most economical choice for longer or higher-dose cycles.
When selecting between tiers, consider that the 10mg format offers the most control and is preferable for first-time oxandrolone users and female athletes, whilst the 50mg format suits seasoned male athletes who have established their individual tolerance and are seeking operational simplicity.
Frequently Asked Questions
What is the difference between 10mg and 50mg oxandrolone tablets for bodybuilding?
The active compound is identical; the difference is purely concentration. 10mg tablets allow fine-grained dose adjustments and suit beginners, female athletes, or those running lower doses of 20–40mg per day. 50mg tablets are more practical for experienced users targeting 50–100mg daily, reducing the number of tablets needed and offering better cost efficiency per milligram at higher dose ranges.
How long does oxandrolone stay active in the body, and how should it be dosed throughout the day?
Oxandrolone has a plasma half-life of approximately 9–10 hours. To maintain stable blood concentrations and maximise consistent anabolic signalling, the total daily dose is typically split into two equal administrations — morning and early evening. A single daily dose is possible but produces more pronounced peak-and-trough fluctuations in serum levels.
Is oxandrolone suitable for a first anabolic steroid cycle?
Oxandrolone is often cited as one of the more accessible oral anabolics for beginners due to its low androgenic rating, absence of aromatisation, and well-studied pharmacology. It does, however, suppress natural testosterone production and carries hepatotoxic potential as a 17α-alkylated compound. Users should research full cycle support protocols and post-cycle therapy before beginning any anabolic steroid regimen.
Fast Acting
